Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference [Yahoo! Finance]
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: Yahoo! Finance
Anavex Life Sciences (NASDAQ:AVXL) is prioritizing upcoming pivotal studies and continued regulatory engagement as it seeks potential pathways to market authorization for its oral central nervous system (CNS) drug candidate blarcamesine, company executives said during a Needham conference session hosted by biotech analyst Ami Fadia. Focus on oral “personalized brain medicine” President and CEO Christopher Missling said the company is “dedicated to address brain health by developing innovative oral medicines designed to improve patient lives,” emphasizing a strategy centered on “convenient oral personalized treatments.” Missling framed Alzheimer's disease as a growing, age-linked unmet need and positioned once-daily oral blarcamesine as a potential fit with patient preferences for simpler treatment regimens. ? 3 Surprising S&P 500 Outperformers of 2026 Missling also highlighted Anavex's broader pipeline across neurodegenerative and neurodevelopmental disorders, including Parki
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s DiseaseGlobeNewswire
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Anavex Life Sciences (AVXL) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.MarketBeat
- Anavex Life Sciences Provides Comprehensive Regulatory Update [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences Provides Comprehensive Regulatory UpdateGlobeNewswire
AVXL
Earnings
- 2/9/26 - Beat
AVXL
Analyst Actions
- 2/10/26 - HC Wainwright
AVXL
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form 8-K
- 2/25/26 - Form 8-K
- AVXL's page on the SEC website